Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 [ICAM-1] in patients with multiple sclerosis

• Autorzy: Niezgoda A , Losy J. , Mehta P.D.
• Języki publikacji: EN

Abstrakty

EN

β-2 Microglobulin (β2M) is a low molecular weight protein located extracellularly and associated with class 1 antigens of the major histocompatibility complex and is considered a marker for disease activity in immune disorders. Cladribine (2-chloro-2-deoxyadenosine, 2-CDA) is a potent lymphocytotoxic agent under investigation in the treatment in MS patients. As β2M levels may indicate inflammatory events in CNS we determined CSF-β2M and serum β2M levels in patients with relapsing-remitting MS before and after cladribine treatment as well as in a control group. There was a significant β2M decrease in sera but not in CSF in MS patients after the cladribine treatment, associated with a slight but significant clinical improvement measured by Kurtzke’s Expanded Disability Status Scale. We also found a significant decrease in sICAM-1 level in CSF but not in sera in MS patients. The data support a role of cladribine in MS therapy and deliver new information on cladribine immunological effects in MS patients.

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2001
• Tom: 60
• Numer: 3
• Opis fizyczny: p.225-228,ref.

Twórcy

autor

Niezgoda A

• University School of Medicine, Przybyszewskiego 49, 60-355 Poznan, Poland

autor

Losy J.

autor

Mehta P.D.

Bibliografia

• 1. Adachi N (1991) Beta-2-microglobulin levels in the cerebrospinal fluid: their value as a disease marker. A review of the recent literature. Eur Neurol, 31: 181–185.
• 2. Alvarez-Cermeno JC, Villar LM, Roy G, Ferreira A, Bootello A, Gimeno A, Gonzalez-Porque P (1987) J Increased beta 2-microglobulin in CSF of multiple sclerosis. Neurol Neurosurg Psychiatry Sep, 50: 1238.
• 3. Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J (1996) Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol, 33: 45–52.
• 4. Beyne P, Lisovoski F, Got L, Ayache P, Delacoux E (1995) Beta-2 microglobulin in cerebrospinal fluid in neurology. Presse Med, 24: 1071–1074.
• 5. Bjerrum OW, Bach FW, Zeeberg I (1988) Increased level cerebrospinal fluid β2-microglobulin is related to neurologic impairment in multiple sclerosis. Acta Neurol Scan, 78: 72–75.
• 6. Cannella B, Raine C (1995) The adhesion molecule and cytokine profile of MS lesions. Ann Neurol, 37: 424–435.
• 7. Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, Beutler E, Carson DA (1990) Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. J Clin Invest, 86: 1480–1488.
• 8. Dore-Duffy P, Newman W, Balabanov R, Lisak RP, Mainolfi E, Rothlein R, Peterson M (1995) Circulating soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis. Neurology, 37: 55–62.
• 9. Droogan AG, Mcmillan SA (1996) Serum and CSF levels of soluble adhesion molecules in MS: predominant intrathecal release of VCAM-1. J Neuroimm, 64: 185–191.
• 10. Grieb P, Stelmasiak Z (1995) Leczenie stwardnienia rozsianego przy pomocy nowego immunosupresanta kladrybiny (2-CDA). Neurol Neurochir Pol, 29: 69–76.
• 11. Hartung HP, Michels M, Reiners K, Seeldrayers P, Archelos JJ, Toyka KV (1993) Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology, 43: 2331–2335.
• 12. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33: 1444–1452.
• 13. Mehta PD, Kulczycki J, Mehta SP, Sobczyk W, Coyle PK, Sersen EA, Wisniewski HM (1992) Increased levels of b2-microglobulin, Soluble Interleukin-2 Receptor, and Soluble CD8 in Patients with Subacute Sclerosing Panencephalitis. Clin Immunol Immunopathol, 65: 3–59.
• 14. Ott M, Demisch L, Engelhardt W, Fischer PA (1993) Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J Neurol, 241: 108–114.
• 15. Piro LD (1992) 2-chlorodeoxyadenosine treatment of lymphoid malignancies. Blood, 79: 843–845.
• 16. Poser CM, Paty DW, Scheinberg L (1983) New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol, 13: 227–231.
• 17. Rodriguez M, Dunkel AJ, Thiemann RL, Leibowitz J, Zijlstra M, Jaenisch R (1993) Abrogation of resistance to Theiler’s virus-induced demyelination in H-2b mice deficient in beta 2-microglobulin. J Immunol, 151: 266–276.
• 18. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E (1996) Development of cladribine treatment in multiple sclerosis. Mult Scler, 1: 343–347.
• 19. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet, 344: 9–13.
• 20. Washington R, Burton J, Todd RF, Newman W, Dragovic L, Dore-Duffy P (1994) Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with MS. Ann Neurol, 35: 89–97.